NCI Designated High Priority Trials as of August 2025

Research Base	Protocol #	Official Study Title	Indication/Disease	Planned Intervention	Abbreviated Eligibility Criteria Please refer to CTSU for the most recent version of the protocol.	Primary Objective	ClinicalTrials.gov NCT #	CTSU Activation Date	Approx. Target Accrual	Note
Alliance	A212102	Blinded Reference Set For Multicancer Early Detection Blood Tests	Patients with confirmed, high suspicion, and without confirmation/suspected cancers.	60 mL (10mL x6 tubes) blood draw within 28 days after registration.	**PVD 4/25/2025** **Eligibility Criteria for Participants with a Cancer Diagnosis*** - Histologically confirmed diagnosis of invasive cancer (synchronous cancers and neuroendocrine tumors are excluded) - One of the tumor types: Colorectal, Bladder, Head and Neck, Hepatobiliary, Lung, Lymphoma, Leukemia, Ovary, Pancreas, Multiple Myeloma, Gastric, esophageal or gastroesophageal, Breast, Kidney, Endometrium, Prostate - No prior definitive systemic or local anti-cancer intervention (including surgical excision) **Eligibility Criteria for Participants without a Cancer Diagnosis and without Suspicion of Cancer*** - Criteria listed in the asterisk (*) below. **Eligibility Criteria for Participants with a High Suspicion of Cancer*** - High suspicion of ovarian cancer, pancreatic cancer, kidney cancer, or melanoma by clinical and/or radiological assessment, with plans for histologic or cytologic confirmation within 28 days after study blood draw - Central review of radiology reports and/or clinical documentation conducted by Study Chairs *** For all 3 categories, patients must:** be age ≥ 40 and ≤ 75; have no known current pregnancy by self-report; have no known or prior history of in situ or invasive malignancy. Non-melanoma skin cancers (such as basal or squamous cell) are allowed; have no history of organ transplantation; have the ability to read and comprehend English or Spanish	To provide a blinded reference set of cancer vs. non-cancer blood samples that will be used to validate assays for inclusion in a prospective clinical trial focused on utility of blood-based multi-cancer early detection.	NCT05334069	8/1/2022	2445	